U.S. markets open in 15 minutes

  • S&P Futures

    4,310.50
    -3.00 (-0.07%)
     

  • Dow Futures

    33,789.00
    -2.00 (-0.01%)
     

  • Nasdaq Futures

    14,705.00
    -34.00 (-0.23%)
     

  • Russell 2000 Futures

    1,793.20
    +0.20 (+0.01%)
     

  • Crude Oil

    93.32
    -0.36 (-0.38%)
     

  • Gold

    1,892.70
    +1.80 (+0.10%)
     

  • Silver

    22.82
    +0.09 (+0.40%)
     

  • EUR/USD

    1.0539
    -0.0037 (-0.35%)
     

  • 10-Yr Bond

    4.6700
    +0.0440 (+0.95%)
     

  • Vix

    18.62
    +0.40 (+2.20%)
     

  • GBP/USD

    1.2191
    +0.0032 (+0.27%)
     

  • USD/JPY

    149.3710
    +0.3720 (+0.25%)
     

  • Bitcoin USD

    26,501.56
    -284.02 (-1.06%)
     

  • CMC Crypto 200

    569.49
    +6.84 (+1.22%)
     

  • FTSE 100

    7,568.76
    -24.46 (-0.32%)
     

  • Nikkei 225

    31,872.52
    -499.38 (-1.54%)
     

Within Two Years Of Public Debut, COVID-19 Test Maker Files For Bankruptcy

1
Vandana Singh
·2 min read

  • Lucira Health Inc (NASDAQ: LHDX) filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

  • The company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code while continuing to support its customers during the process.

  • Lucira Health snowballed over the past several years amid the COVID-19 pandemic. Demand for the company's COVID-19 test kits surged, and it posted positive net income in its 2022 first quarter for the first time since its inception.

  • The company anticipated an Emergency Use Authorization for an OTC indication on the COVID-19 and Flu test in August 2022. However, the FDA's approval process became protracted, resulting in high expenditures without new revenue from the combined test kit during the 2022-2023 flu season.

  • Last month, Lucira Health submitted a EUA application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.

  • Lucira's test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in November 2022.

  • In October 2022, Lucira's Board of Directors approved various initiatives to rebalance its cost structure and explore strategic alternatives.

  • In 2021, Lucira Health launched an upsized IPO of 9 million shares at $17 per share for expected gross proceeds of $153 million.

  • Price Action: LHDX shares are down 36.30% at $0.15 during the premarket session on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Within Two Years Of Public Debut, COVID-19 Test Maker Files For Bankruptcy originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.